A novel method to detect articular chondrocyte death during early stages of osteoarthritis using a non-invasive ApoPep-1 probe

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Che, Xiangguo ^a   Chi, Lianhua ^a   Park, Clara Yongjoo ^a   Cho, Gyoung Ho ^a   Park, Narae ^a   Kim, Seong Gon ^b   Lee, Byung Heon ^a   Choi, Je Yong ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Gangneung Wonju National University   (South Korea)

Author keywords

ApoPep 1; Apoptosis; Articular chondrocyte; Early diagnosis of osteoarthritis

Indexed keywords

COLLAGEN TYPE 2; CYSTEINYLGLUTAMINYLARGINYLPROPYLPROPYLARGININE; HISTONE H1; POLYPEPTIDE; UNCLASSIFIED DRUG; CYSTEINYL-GLUTAMINYL-ARGINYL-PROLYL-PROLYL-ARGININE; OLIGOPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CELL DEATH; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUNEL ASSAY; ANIMAL; APOPTOSIS; C57BL MOUSE; CHONDROCYTE; DIAGNOSTIC IMAGING; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; APOPTOSIS; CHONDROCYTES; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; FLUORESCENT ANTIBODY TECHNIQUE; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; OSTEOARTHRITIS;

EID: 84946748104     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0832-x     Document Type: Article

References (56)

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25.
3. Rolauffs B, Williams JM, Aurich M, Grodzinsky AJ, Kuettner KE, Cole AA. Proliferative remodeling of the spatial organization of human superficial chondrocytes distant from focal early osteoarthritis. Arthritis Rheum. 2010;62:489-98.
4. Bay-Jensen AC, Hoegh-Madsen S, Dam E, Henriksen K, Sondergaard BC, Pastoureau P, et al. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int. 2010;30:435-42.
5. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013;9:654-64.
6. Wise BL, Felson DT, Clancy M, Niu J, Neogi T, Lane NE, et al. Consistency of knee pain and risk of knee replacement: the Multicenter Osteoarthritis Study. J Rheumatol. 2011;38:1390-5.
7. Patra D, Sandell LJ. Evolving biomarkers in osteoarthritis. J Knee Surg. 2011;24:241-9.
8. Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii78-81.
9. Hosseininia S, Lindberg LR, Dahlberg LE. Cartilage collagen damage in hip osteoarthritis similar to that seen in knee osteoarthritis; a case-control study of relationship between collagen, glycosaminoglycan and cartilage swelling. BMC Musculoskelet Disord. 2013;14:18.
10. Hashimoto S, Rai MF, Janiszak KL, Cheverud JM, Sandell LJ. Cartilage and bone changes during development of post-traumatic osteoarthritis in selected LGXSM recombinant inbred mice. Osteoarthritis Cartilage. 2012;20:562-71.
11. Ling SM, Fried LP, Garrett ES, Fan MY, Rantanen T, Bathon JM. Knee osteoarthritis compromises early mobility function: The Women's Health and Aging Study II. J Rheumatol. 2003;30:114-20.
12. Lires-Dean M, Carames B, Cillero-Pastor B, Galdo F, Lopez-Armada MJ, Blanco FJ. Anti-apoptotic effect of transforming growth factor-beta1 on human articular chondrocytes: role of protein phosphatase 2A. Osteoarthritis Cartilage. 2008;16:1370-8.
13. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat Rev Rheumatol. 2011;7:161-9.
14. Kawaguchi H. Endochondral ossification signals in cartilage degradation during osteoarthritis progression in experimental mouse models. Mol Cells. 2008;25:1-6.
15. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19:704-12.
16. Poole AR, Rosenberg LC, Reiner A, Ionescu M, Bogoch E, Roughley PJ. Contents and distributions of the proteoglycans decorin and biglycan in normal and osteoarthritic human articular cartilage. J Orthop Res. 1996;14:681-9.
17. Stoop R, Buma P, van der Kraan PM, Hollander AP, Billinghurst RC, Meijers TH, et al. Type II collagen degradation in articular cartilage fibrillation after anterior cruciate ligament transection in rats. Osteoarthritis Cartilage. 2001;9:308-15.
18. Mitchell N, Lee ER, Shepard N. The clones of osteoarthritic cartilage. J Bone Joint Surg Br Volume. 1992;74:33-8.
19. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest. 1995;96:2859-69.
20. Almonte-Becerril M, Navarro-Garcia F, Gonzalez-Robles A, Vega-Lopez MA, Lavalle C, Kouri JB. Cell death of chondrocytes is a combination between apoptosis and autophagy during the pathogenesis of Osteoarthritis within an experimental model. Apoptosis. 2010;15:631-8.
21. Del Carlo JM, Loeser RF. Cell death in osteoarthritis. Curr Rheumatol Rep. 2008;10:37-42.
22. Heraud F, Heraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann Rheum Dis. 2000;59:959-65.
23. Todd Allen R, Robertson CM, Harwood FL, Sasho T, Williams SK, Pomerleau AC, et al. Characterization of mature vs aged rabbit articular cartilage: analysis of cell density, apoptosis-related gene expression and mechanisms controlling chondrocyte apoptosis. Osteoarthritis Cartilage. 2004;12:917-23.
24. Thomas CM, Fuller CJ, Whittles CE, Sharif M. Chondrocyte death by apoptosis is associated with the initiation and severity of articular cartilage degradation. Int J Rheum Dis. 2011;14:191-8.
25. Aigner T, Hemmel M, Neureiter D, Gebhard PM, Zeiler G, Kirchner T, et al. Apoptotic cell death is not a widespread phenomenon in normal aging and osteoarthritis human articular knee cartilage: a study of proliferation, programmed cell death (apoptosis), and viability of chondrocytes in normal and osteoarthritic human knee cartilage. Arthritis Rheum. 2001;44:1304-12.
26. Ramos YF, Bos SD, Lakenberg N, Bohringer S, den Hollander WJ, Kloppenburg M, et al. Genes expressed in blood link osteoarthritis with apoptotic pathways. Ann Rheum Dis. 2014;73:1844-53.
27. Smith G, Nguyen QD, Aboagye EO. Translational imaging of apoptosis. Anti Cancer Agents Med Chem. 2009;9:958-67.
28. Tait JF. Imaging of apoptosis. J Nucl Med. 2008;49:1573-6.
29. Blankenberg FG. In vivo detection of apoptosis. Eur J Nucl Med. 2008;49:81S-95S.
30. Reid DL, Aydelotte MB, Mollenhauer J. Cell attachment, collagen binding, and receptor analysis on bovine articular chondrocytes. J Orthop Res. 2000;18:364-73.
31. von der Mark K, Mollenhauer J. Annexin V interactions with collagen. Cell Mol Life Sci. 1997;53:539-45.
32. Kim HJ, Kirsch T. Collagen/annexin V interactions regulate chondrocyte mineralization. J Biol Chem. 2008;283:10310-7.
33. Kirsch T, Pfaffle M. Selective binding of anchorin CII (annexin V) to type II and X collagen and to chondrocalcin (C-propeptide of type II collagen). Implications for anchoring function between matrix vesicles and matrix proteins. FEBS Lett. 1992;310:143-7.
34. Kao DJ, Hodges RS. Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa. Chem Biol Drug Des. 2009;74:33-42.
35. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 2003;9:123-8.
36. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt. 2001;6:122-33.
37. Moon WK, Lin Y, O'Loughlin T, Tang Y, Kim DE, Weissleder R, et al. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem. 2003;14:539-45.
38. Wang K, Purushotham S, Lee JY, Na MH, Park H, Oh SJ, et al. In vivo imaging of tumor apoptosis using histone H1-targeting peptide. J Control Release. 2010;148:283-91.
39. Wu D, Ingram A, Lahti JH, Mazza B, Grenet J, Kapoor A, et al. Apoptotic release of histones from nucleosomes. J Biol Chem. 2002;277:12001-8.
40. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol. 2004;172:6692-700.
41. Chen R, Kang R, Fan XG, Tang D. Release and activity of histone in diseases. Cell Death Dis. 2014;5:e1370.
42. Lee MJ, Wang K, Kim IS, Lee BH, Han HS. Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide. Mol Imaging Biol. 2012;14:147-55.
43. Wang K, Na MH, Hoffman AS, Shim G, Han SE, Oh YK, et al. In situ dose amplification by apoptosis-targeted drug delivery. J Control Release. 2011;154:214-7.
44. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15:1061-9.
45. Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H, Yamada T, et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthritis Cartilage. 2005;13:632-41.
46. Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2006;14:13-29.
47. Palmer AJ, Brown CP, McNally EG, Price AJ, Tracey I, Jezzard P, et al. Non-invasive imaging of cartilage in early osteoarthritis. Bone Joint J. 2013;95-B:738-46.
48. Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, et al. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell. 2007;6:745-57.
49. Nissen-Meyer LS, Popescu MC, el Hamdani H, Chaudhry FA. Protein kinase C-mediated phosphorylation of a single serine residue on the rat glial glutamine transporter SN1 governs its membrane trafficking. J Neurosci. 2011;31:6565-75.
50. Bellamy N. Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthritis Cartilage. 1999;7:424-6.
51. Pelletier JP. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12(Suppl A):S63-8.
52. Richette P, Bardin T. Structure-modifying agents for osteoarthritis: an update. Joint Bone Spine. 2004;71:18-23.
53. Altman RD. Structure-/disease-modifying agents for osteoarthritis. Semin Arthritis Rheum. 2005;34:3-5.
54. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001;44:585-94.
55. Yan N, Shi Y. Histone H1.2 as a trigger for apoptosis. Nat Struct Biol. 2003;10:983-5.
56. Wheaton AJ, Dodge GR, Borthakur A, Kneeland JB, Schumacher HR, Reddy R. Detection of changes in articular cartilage proteoglycan by T(1rho) magnetic resonance imaging. J Orthop Res. 2005;23:102-8.